Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema
Oculis reported topline Phase 3 DIAMOND-1 and DIAMOND-2 results for OCS-01 eye drops in diabetic macular edema. The primary BCVA (ETDRS) endpoint at week 52 was not met in either trial, and the ≥15-letter BCVA gain secondary endpoint also was not met. Retinal thickness decreased persistently vs vehicle. Oculis said it will not pursue an FDA filing for DME. Cash: $278M (as of Mar. 31, 2026).
How this was made
The 30-second read
Why it matters
The primary BCVA endpoint was not met in both trials, and the key secondary ≥15-letter BCVA gain proportion was also not met; management de-prioritizes DME by not planning an FDA filing, reallocating resources to other registrational assets.
Market read
This is a direct clinical-development and regulatory-decision update for OCS-01 in DME, with explicit resource reallocation and a near-term catalyst (4:30 pm ET call).
What to watch
Investors may refocus on the cash runway ($278M) and the separate late-stage registrational programs (Privosegtor PIONEER; Licaminlimab PREDICT-1), which can partially offset DME disappointment.
Background
Oculis’ DIAMOND program evaluated OCS-01 eye drops in diabetic macular edema over 52 weeks in two Phase 3, double-masked randomized trials.
Ticker impact
Oculis reports Phase 3 DIAMOND-1/2 topline results for OCS-01 in diabetic macular edema, with the primary BCVA endpoint missed and no FDA filing planned.
Near-term downside bias on risk-off biotech sentiment; magnitude depends on how investors price pipeline value beyond OCS-01.
The company explicitly states it will not pursue an FDA regulatory filing for OCS-01 in DME after failing primary and key secondary BCVA endpoints, reallocating resources to other registrational trials.
Market effects
Adds evidence that retinal thickness improvements may not translate into functional vision gains for ophthalmic topical therapies, potentially affecting read-across sentiment.
Primarily impacts US-listed biotech sentiment (Nasdaq: OCS) with potential spillover to ophthalmology peers.
Global clinical-development risk sentiment for late-stage ophthalmology programs; execution and safety signals may temper total drawdown.
Counterpoint
Persistent retinal thickness reduction and acceptable safety could still support alternative endpoints, subgroups, or future reformulations, even without an immediate FDA filing.
Key entities
- companyOculis
Nasdaq-listed biopharma running Phase 3 DIAMOND trials for OCS-01 in diabetic macular edema; topline results missed primary endpoint and no FDA filing planned.
- drug_candidateOCS-01
Oculis’ eye-drop candidate evaluated in DIAMOND-1 and DIAMOND-2 for diabetic macular edema.
- drug_candidatePrivosegtor
Neuroprotective candidate in the Privosegtor PIONEER registrational program for optic neuropathies.
- drug_candidateLicaminlimab
Topical anti-TNFα candidate in the Licaminlimab PREDICT-1 registrational trial for dry eye disease.
